Windrose Consulting Group is delighted to welcome two new team members to our UK and Switzerland offices.

Windrose Consulting Group is thrilled to welcome Gordon Bache as a Partner in our London, UK office.

Windrose Consulting Group Welcomes Eric E. Bayir as Engagement Manager in the U.S. Office.

We’re thrilled to announce the promotion of twelve outstanding team members at Windrose Consulting Group.

Windrose Consulting Group is pleased to welcome Sam Symons to our US office as an Analyst.

Historically, Germany has been the only country in Europe to maintain transparent list-net pricing. However, the 2022 AMNOG guardrails set the pricing opportunity relative to the G-BA outcome, whereby “No Additional Benefit” rating can result in price parity with off-patent comparators.

Registration is now open for Developing a Successful Biopharmaceutical Pricing & Market Access Strategy, Thursdays, from April 24th until June 12th 2025 (1pm – 3 pm BST).

Download the report to find out about the Turkish pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Download the report to find out about the Saudi Arabian pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Download the report to find out about the Japanese pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Download the report to find out about the Chinese pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Download the report to find out about the Brazilian pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Our client was launching a novel therapy for the treatment of Ulcerative Colitis (UC) and wanted to assess the strategic potential of patient affordability solutions across 13 international markets

The client had developed and launched a human papillomavirus (HPV) vaccine which was reimbursed for adolescents through national immunization programs for only some markets

The client developed an innovative treatment for sickle cell disease (SCD) and wanted to assess the payer and self-pay landscape, understand barriers to funding / purchase decisions, and identify affordability solutions to support access to Product X across markets in-scope

The client was preparing for an indication expansion of Product X, which was already indicated in other blood conditions, into alpha-thalassemia, an inherited blood disorder

The FDA issued guidance for new products in chronic weight management setting a threshold for their efficacy to be at least a 5% mean change from baseline in body weight vs. placebo at 1 year.

Windrose Consulting Group is excited to announce the promotion of three outstanding team members to Partner level.

Download the report to find out about the French pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Windrose Consulting Group are pleased to welcome the latest members of our team into the London office